ARTICLE | Company News
Phenex, Gilead deal
January 12, 2015 8:00 AM UTC
Gilead acquired Phenex’s farnesoid X receptor (FXR; NR1H4) program for an undisclosed upfront payment plus up to $470 million in milestone payments. The companies declined to disclose further detail...